Selvita And Orion Pharma Will Collaborate on SEL103 - Alzheimer’s Disease Program
SUMMARY Orion Corporation and Selvita have agreed to collaborate on further research and development of Selvita’s SEL103 program, for the symptomatic treatment of Alzheimer’s disease. The agreement provides for an initial up-front payment to Selvita …